Actelion Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACTELION, and when can generic versions of ACTELION drugs launch?
ACTELION has eight approved drugs.
There are fifteen US patents protecting ACTELION drugs.
There are two hundred and forty-seven patent family members on ACTELION drugs in thirty-nine countries and thirty-four supplementary protection certificates in seventeen countries.
Summary for Actelion
International Patents: | 247 |
US Patents: | 15 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 8 |
PTAB Cases with Actelion as petitioner: | See PTAB cases with Actelion as petitioner |
Drugs and US Patents for Actelion
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | TRACLEER | bosentan | TABLET, FOR SUSPENSION;ORAL | 209279-001 | Sep 5, 2017 | RX | Yes | Yes | 7,959,945 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-002 | Dec 21, 2015 | AB | RX | Yes | Yes | 10,821,108 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Actelion | OPSUMIT | macitentan | TABLET;ORAL | 204410-001 | Oct 18, 2013 | AB | RX | Yes | Yes | 8,367,685 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | AB | RX | Yes | No | 10,821,108 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Actelion | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-001 | Dec 29, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | 10,821,108 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Actelion
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,472,969 | ⤷ Try a Trial |
Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,525,616 | ⤷ Try a Trial |
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Oral Suspension | 32 mg | ➤ Subscribe | 2019-02-08 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2017-10-18 |
International Patents for Actelion Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6825574 | ⤷ Try a Trial |
Spain | 2336943 | ⤷ Try a Trial |
Philippines | 12018501161 | ⤷ Try a Trial |
Poland | 2059246 | ⤷ Try a Trial |
Canada | 2641393 | ⤷ Try a Trial |
Japan | WO2002088084 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Actelion Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1400518 | 93266 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519 |
1345920 | SPC/GB14/018 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220 |
1345920 | 502 | Finland | ⤷ Try a Trial | |
2447254 | PA2018008 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512 |
1345920 | 2014/018 | Ireland | ⤷ Try a Trial | PRODUCT NAME: MACITENTAN, THE STEREOISOMERS AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/13/893 20131220 |
0526708 | 02C0042 | France | ⤷ Try a Trial | PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.